Core Insights - Tempus AI (NASDAQ:TEM) is recognized as one of the top stocks to buy in Cathie Wood's 2026 Portfolio, leveraging AI to enhance patient treatment through data analysis [1] - The company has seen a significant increase in hedge fund interest, with 41 out of 1041 tracked hedge funds holding stakes in Tempus AI by the end of last year, up from 32 funds in September [1] - Tempus AI's stock has appreciated approximately 17% over the past year, driven by rising demand for its genomic testing and data tools [2] Financial Performance - In Q4, Tempus AI reported a revenue increase of over 80% year-over-year, with adjusted EBITDA turning positive [2] - The revenue outlook for 2026 indicates a growth rate of 25%, which, while slower than the previous year, still exceeds Wall Street's expectations [2] Market Position - Tempus AI's platform is now integrated with over 5,000 healthcare providers across the U.S., reflecting its expanding market presence [2]